MAIA Biotechnology shares are trading lower. The company reported new clinical data from its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who failed 2 or more standard-of-care therapy regimens.
Portfolio Pulse from Benzinga Newsdesk
MAIA Biotechnology shares are trading lower after the company reported new clinical data from its Phase 2 THIO-101 clinical trial. The trial evaluates THIO sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who failed 2 or more standard-of-care therapy regimens.
June 04, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
MAIA Biotechnology shares are trading lower following the release of new clinical data from its Phase 2 THIO-101 trial. The data pertains to the use of THIO with cemiplimab in patients with advanced non-small cell lung cancer who have not responded to standard treatments.
The decline in MAIA Biotechnology's share price is directly linked to the release of new clinical data from its Phase 2 THIO-101 trial. Investors likely reacted negatively to the results, which may not have met expectations for efficacy or safety in treating advanced non-small cell lung cancer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100